Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Sab Biotherapeutics Inc WT (SABSW)

Sab Biotherapeutics Inc WT (SABSW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update GlobeNewswire - Wed Nov 6, 4:05PM CST

SABSW : 0.0730 (+9.12%)
SABS : 3.13 (+1.95%)
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference GlobeNewswire - Thu Oct 31, 6:00AM CDT

SABSW : 0.0730 (+9.12%)
SABS : 3.13 (+1.95%)
SAB Biotherapeutics Provides Company Update for Q2 2022 Financial Results Globe Newswire - Wed Aug 10, 2022

Expects cash is sufficient to fund operations for the forward twelve months...

SABS : 3.13 (+1.95%)
SABSW : 0.0730 (+9.12%)
SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down Globe Newswire - Tue Aug 9, 2022

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel...

SABS : 3.13 (+1.95%)
SABSW : 0.0730 (+9.12%)
SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer Globe Newswire - Mon Jun 6, 2022

SIOUX FALLS, S.D., June 06, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel...

SABS : 3.13 (+1.95%)
SABSW : 0.0730 (+9.12%)
SAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering Summit Globe Newswire - Tue May 31, 2022

In-person presentation titled ‘Leveraging Genetically Engineered Ungulates to Produce Novel Human Biotherapeutics’ to take place on June 7 in Park City,...

SABS : 3.13 (+1.95%)
SABSW : 0.0730 (+9.12%)
SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results Globe Newswire - Thu May 12, 2022

Full data from Phase 2a trial that evaluated SAB-176 for treatment of seasonal influenza expected third quarter 2022 – first clinical data set from novel...

SABS : 3.13 (+1.95%)
SABSW : 0.0730 (+9.12%)
SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference Globe Newswire - Thu May 12, 2022

SIOUX FALLS, S.D., May 12, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), announced today its participation at the H.C. Wainwright Global...

SABSW : 0.0730 (+9.12%)
SABS : 3.13 (+1.95%)
SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors Globe Newswire - Tue Apr 5, 2022

SIOUX FALLS, S.D., April 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel...

SABS : 3.13 (+1.95%)
SABSW : 0.0730 (+9.12%)
SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results Globe Newswire - Tue Mar 29, 2022

SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised...

SABS : 3.13 (+1.95%)
SABSW : 0.0730 (+9.12%)

Barchart Exclusives

3 High-Yielding Dividend Kings to Boost Your Income in 2025 and Beyond Barchart - Fri Nov 22, 6:00PM CST
These three high-quality companies are currently on sale, offering elevated yields that appeal to dividend growth investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot